Name | Relationship | Address | Signature | Signature date | CIK |
---|---|---|---|---|---|
Ho Carole | Director | C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK | /s/ Sean Weisberg, as Attorney-in-Fact for Carole Ho | 2025-07-31 | 0001724605 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | RPRX | Class A Ordinary Shares | Award | $0 | +2.75K | $0.00 | 2.75K | Jul 31, 2025 | Direct | F1 | |
transaction | RPRX | Class A Ordinary Shares | Award | $0 | +5.81K | +210.97% | $0.00 | 8.56K | Jul 31, 2025 | Direct | F2 |
Id | Content |
---|---|
F1 | Reflects an initial equity award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. |
F2 | Reflects a pro-rated annual equity award of restricted stock units under the Plan that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. |